The move to reclassify cannabis from a Schedule I to a Schedule III drug could spark new studies into pain, aging and women's health, Dr. Staci Gruber tells GBH's All Things Considered.

Moving cannabis to a category of drugs that includes some common medicines will have implications for research, businesses ...

President Trump signed an order to reschedule marijuana to a lower drug classification, one of the most significant changes ...

Cannabis may be on its way to being less restricted in the U.S. after a recent recommendation from the Health and Human Services Department to reschedule the drug's classification. Last week, the HHS ...

This study analyzes 20 years of data from the Food and Drug Administration’s Adverse Event Reporting System (FAERS) to reveal trends in drug-induced fatty liver disease (DIFLD), identifying high-risk ...